<DOC>
	<DOCNO>NCT00332995</DOCNO>
	<brief_summary>This Phase I trial ass feasibility use vaginal ring deliver candidate microbicide dapivirine ( TMC120 ) 7 day . The study population consist 13 healthy , sexually abstinent woman . Safety tolerability assess clinical laboratory assessment . Feasibility drug delivery assess measure dapivirine ( TMC120 ) concentration vaginal fluid , vaginal cervical epithelial tissue , plasma .</brief_summary>
	<brief_title>Safety Feasibility Study Dapivirine ( TMC120 ) Vaginal Ring Belgium</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Female , age 1850 year Willing able provide write informed consent HIVuninfected otherwise healthy Willing abstain sexual activity use vaginal product participate study Currently use oral contraceptive pregnancy prevention Willing use oral contraceptive need avoid menstruation take part study History allergy TMC120 constituents vaginal ring History diagnosis and/or treatment sexually transmit disease within last three month History genital tract surgery within last month Currently pregnant breastfeeding , within two month last pregnancy outcome Currently within one month participate clinical research study Current vulvar vaginal symptom / abnormality could influence study result Current noniatrogenic pelvic/colposcopic exam finding involve deep epithelial disruption Current diagnosis genital infection Smoking 10 cigarette / day</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>HIV Seronegativity</keyword>
</DOC>